Maintenance therapy in NSCLC: why? To whom? Which agent?-Reference-Cited by-同舟云学术

Maintenance therapy in NSCLC: why? To whom? Which agent?

Published:2011-05-06 Issue:1 Volume:30 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Novello Silvia,Milella Michele,Tiseo Marcello,Banna Giuseppe,Cortinovis Diego,Di Maio Massimo,Garassino Marina,Maione Paolo,Martelli Olga,Vavalà Tiziana,Bria Emilio

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1756-9966-30-50.pdf

Reference47 articles.

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics 2010. CA Cancer J Clin. 2010, 60:

2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J: Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic and end results database. J Clin Oncol. 2006, 24: 4539-4544. 10.1200/JCO.2005.04.4859.

3. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C: Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005, 128: 452-462. 10.1378/chest.128.1.452.

4. Reck M, Von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Leighl N, J Mezger, Archer V, Moore N, Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small cell lung cancer: AVAIL. J Clin Oncol. 2009, 27: 1227-1234. 10.1200/JCO.2007.14.5466.

5. Sandler A, Gray R, Perry MC, Brhamer J, Schiller JH, Dowlati A, Lilembaum R, Johnson DH: Paclitaxel-Carboplatin alone or with bevacizumab for non-small cell lung cancer. New England J Med. 2006, 355: 2542-2550. 10.1056/NEJMoa061884.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy;Journal of Chemotherapy;2024-09

2. Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting;Journal of Thoracic Disease;2021-03

3. Filtering Data About Treatment-Induced Renal Injury: From Biology to Practice;Journal of Thoracic Oncology;2020-09

4. Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm;Oncology Reviews;2020-07-21

5. Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors;Frontiers in Oncology;2020-02-12